Alicia Morgans, MD, MPH, on the Rationale for Examining the Clinical and Cost Impact of Cabazitaxel in mCRPC

Contemporary Concepts | Contemporary Concepts in Prostate Cancer | <b>Management of Financial Toxicity</b>

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology Congress to talk about the rationale for analyzing the financial impact of cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.

At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of the Survivorship Program at Dana-Farber Cancer Institute, about the rationale for the phase 4 CARD trial (NCT02485691), wherein investigators assessed the clinical and financial impact of treatment with cabazitaxel (Jevtana) compared with a second androgen receptor (AR) targeted agent in patients with metastatic castration-resistant prostate cancer (mCRPC).

Morgans explained how experienced beyond outcomes, such as financial stress and complications can have an impact on patients’ lives.


We performed a health resource utilization or health economics analysis of the way that cabazitaxel vs an AR-targeted agent affects the costs and the time spent having complications that patients might experience if they’re receiving cabazitaxel vs that other alternate AR-targeted agent in the third-line setting for mCRCP. This work is important for patients, because at the end of the day, they experience things that are not necessarily just related to cancer outcomes. Cancer control is 1 piece of their experience, but of course, the financial stresses they may experience and the time they may have to spend in a hospital or dealing with complications can be an impactful thing on their lives as well. This work is meant to quantify some of the other pieces of that experience.


Morgans AK, Hutson TE, Guan AK, et al. Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide). Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021; Virtual. Accessed September 28. 2021.Abstract 587P.